Cargando…

TDP‐43 and tau concurrence in the entorhinal subfields in primary age‐related tauopathy and preclinical Alzheimer's disease

Phosphorylated tau (p‐tau) pathology correlates strongly with cognitive decline and is a pathological hallmark of Alzheimer's Disease (AD). In recent years, phosphorylated transactive response DNA‐binding protein (pTDP‐43) has emerged as a common comorbidity, found in up to 70% of all AD cases...

Descripción completa

Detalles Bibliográficos
Autores principales: Llamas‐Rodríguez, Josué, Oltmer, Jan, Marshall, Michael, Champion, Samantha, Frosch, Matthew P., Augustinack, Jean C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307525/
https://www.ncbi.nlm.nih.gov/pubmed/37037195
http://dx.doi.org/10.1111/bpa.13159
_version_ 1785066067686588416
author Llamas‐Rodríguez, Josué
Oltmer, Jan
Marshall, Michael
Champion, Samantha
Frosch, Matthew P.
Augustinack, Jean C.
author_facet Llamas‐Rodríguez, Josué
Oltmer, Jan
Marshall, Michael
Champion, Samantha
Frosch, Matthew P.
Augustinack, Jean C.
author_sort Llamas‐Rodríguez, Josué
collection PubMed
description Phosphorylated tau (p‐tau) pathology correlates strongly with cognitive decline and is a pathological hallmark of Alzheimer's Disease (AD). In recent years, phosphorylated transactive response DNA‐binding protein (pTDP‐43) has emerged as a common comorbidity, found in up to 70% of all AD cases (Josephs et al., Acta Neuropathol, 131(4), 571–585; Josephs, Whitwell, et al., Acta Neuropathol, 127(6), 811–824). Current staging schemes for pTDP‐43 in AD and primary age‐related tauopathy (PART) track its progression throughout the brain, but the distribution of pTDP‐43 within the entorhinal cortex (EC) at the earliest stages has not been studied. Moreover, the exact nature of p‐tau and pTDP‐43 co‐localization is debated. We investigated the selective vulnerability of the entorhinal subfields to phosphorylated pTDP‐43 pathology in preclinical AD and PART postmortem tissue. Within the EC, posterior‐lateral subfields showed the highest semi‐quantitative pTDP‐43 density scores, while the anterior‐medial subfields had the lowest. On the rostrocaudal axis, pTDP‐43 scores were higher posteriorly than anteriorly (p < 0.010), peaking at the posterior‐most level (p < 0.050). Further, we showed the relationship between pTDP‐43 and p‐tau in these regions at pathology‐positive but clinically silent stages. P‐tau and pTDP‐43 presented a similar pattern of affected subregions (p < 0.0001) but differed in density magnitude (p < 0.0001). P‐tau burden was consistently higher than pTDP‐43 at every anterior–posterior level and in most EC subfields. These findings highlight pTDP‐43 burden heterogeneity within the EC and the posterior‐lateral subfields as the most vulnerable regions within stage II of the current pTDP‐43 staging schemes for AD and PART. The EC is a point of convergence for p‐tau and pTDP‐43 and identifying its most vulnerable neuronal populations will prove key for early diagnosis and disease intervention.
format Online
Article
Text
id pubmed-10307525
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-103075252023-06-30 TDP‐43 and tau concurrence in the entorhinal subfields in primary age‐related tauopathy and preclinical Alzheimer's disease Llamas‐Rodríguez, Josué Oltmer, Jan Marshall, Michael Champion, Samantha Frosch, Matthew P. Augustinack, Jean C. Brain Pathol Research Articles Phosphorylated tau (p‐tau) pathology correlates strongly with cognitive decline and is a pathological hallmark of Alzheimer's Disease (AD). In recent years, phosphorylated transactive response DNA‐binding protein (pTDP‐43) has emerged as a common comorbidity, found in up to 70% of all AD cases (Josephs et al., Acta Neuropathol, 131(4), 571–585; Josephs, Whitwell, et al., Acta Neuropathol, 127(6), 811–824). Current staging schemes for pTDP‐43 in AD and primary age‐related tauopathy (PART) track its progression throughout the brain, but the distribution of pTDP‐43 within the entorhinal cortex (EC) at the earliest stages has not been studied. Moreover, the exact nature of p‐tau and pTDP‐43 co‐localization is debated. We investigated the selective vulnerability of the entorhinal subfields to phosphorylated pTDP‐43 pathology in preclinical AD and PART postmortem tissue. Within the EC, posterior‐lateral subfields showed the highest semi‐quantitative pTDP‐43 density scores, while the anterior‐medial subfields had the lowest. On the rostrocaudal axis, pTDP‐43 scores were higher posteriorly than anteriorly (p < 0.010), peaking at the posterior‐most level (p < 0.050). Further, we showed the relationship between pTDP‐43 and p‐tau in these regions at pathology‐positive but clinically silent stages. P‐tau and pTDP‐43 presented a similar pattern of affected subregions (p < 0.0001) but differed in density magnitude (p < 0.0001). P‐tau burden was consistently higher than pTDP‐43 at every anterior–posterior level and in most EC subfields. These findings highlight pTDP‐43 burden heterogeneity within the EC and the posterior‐lateral subfields as the most vulnerable regions within stage II of the current pTDP‐43 staging schemes for AD and PART. The EC is a point of convergence for p‐tau and pTDP‐43 and identifying its most vulnerable neuronal populations will prove key for early diagnosis and disease intervention. John Wiley and Sons Inc. 2023-04-10 /pmc/articles/PMC10307525/ /pubmed/37037195 http://dx.doi.org/10.1111/bpa.13159 Text en © 2023 The Authors. Brain Pathology published by John Wiley & Sons Ltd on behalf of International Society of Neuropathology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research Articles
Llamas‐Rodríguez, Josué
Oltmer, Jan
Marshall, Michael
Champion, Samantha
Frosch, Matthew P.
Augustinack, Jean C.
TDP‐43 and tau concurrence in the entorhinal subfields in primary age‐related tauopathy and preclinical Alzheimer's disease
title TDP‐43 and tau concurrence in the entorhinal subfields in primary age‐related tauopathy and preclinical Alzheimer's disease
title_full TDP‐43 and tau concurrence in the entorhinal subfields in primary age‐related tauopathy and preclinical Alzheimer's disease
title_fullStr TDP‐43 and tau concurrence in the entorhinal subfields in primary age‐related tauopathy and preclinical Alzheimer's disease
title_full_unstemmed TDP‐43 and tau concurrence in the entorhinal subfields in primary age‐related tauopathy and preclinical Alzheimer's disease
title_short TDP‐43 and tau concurrence in the entorhinal subfields in primary age‐related tauopathy and preclinical Alzheimer's disease
title_sort tdp‐43 and tau concurrence in the entorhinal subfields in primary age‐related tauopathy and preclinical alzheimer's disease
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307525/
https://www.ncbi.nlm.nih.gov/pubmed/37037195
http://dx.doi.org/10.1111/bpa.13159
work_keys_str_mv AT llamasrodriguezjosue tdp43andtauconcurrenceintheentorhinalsubfieldsinprimaryagerelatedtauopathyandpreclinicalalzheimersdisease
AT oltmerjan tdp43andtauconcurrenceintheentorhinalsubfieldsinprimaryagerelatedtauopathyandpreclinicalalzheimersdisease
AT marshallmichael tdp43andtauconcurrenceintheentorhinalsubfieldsinprimaryagerelatedtauopathyandpreclinicalalzheimersdisease
AT championsamantha tdp43andtauconcurrenceintheentorhinalsubfieldsinprimaryagerelatedtauopathyandpreclinicalalzheimersdisease
AT froschmatthewp tdp43andtauconcurrenceintheentorhinalsubfieldsinprimaryagerelatedtauopathyandpreclinicalalzheimersdisease
AT augustinackjeanc tdp43andtauconcurrenceintheentorhinalsubfieldsinprimaryagerelatedtauopathyandpreclinicalalzheimersdisease